Janssen Pharmaceutical Inc.
1125 Trenton-Harbourton Road
Titusville
New Jersey
08560
United States
Tel: 609-730-2000
Website: https://www.janssen.com/
500 articles with Janssen Pharmaceutical Inc.
-
Gilead has announced they are pulling cancer drug Zydelig (idelalisib) off the market for certain types of cancer after failing to complete follow-up clinical trials to confirm efficacy and safety.
-
Leyden Labs Licenses Pan-Influenza Antibody from Janssen
1/18/2022
Leyden Laboratories B.V., announces the development of an intranasal spray protecting against influenza A and influenza B based on the human monoclonal antibody CR9114.
-
As 2022 gets underway, multiple companies have already announced partnerships that will advance the potential for new medications in various disease indications.
-
Korea Economic Daily, published a story saying that Samsung Group was in talks to acquire Biogen. However, Samsung BioLogics stated in a regulatory filing yesterday that the rumor is not true.
-
Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
12/29/2021
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of teclistamab for the treatment of patients with relapsed or refractory (R/R) multiple myeloma.
-
At the median follow-up of about eight months, the overall response rate (ORR) was 62% at the recommended subcutaneous (SC) Phase II dose of 1.5 mg/kg.
-
Janssen Pharmaceutical says goodbye to San Francisco’s Theravance Biopharma after a disappointing performance from a drug the two companies were developing together.
-
FDA Approves Two New Indications for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
12/21/2021
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. FDA has approved two pediatric indications for XARELTO®: the treatment of venous thromboembolism and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis in children aged two years and older with congenital heart disease who have undergone the Fontan procedure.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
At the ASH meeting, Bristol Myers Squibb and Kite Pharma presented promising data from CAR-T programs aimed at relapsed or refractory large B-cell lymphoma.
-
New Data from CARTITUDE-1 Study Show Continued Deep and Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
12/12/2021
The Janssen Pharmaceutical Companies of Johnson & Johnson announced longer-term results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of ciltacabtagene autoleucel, an investigational B-cell maturation antigen -directed chimeric antigen receptor T-cell therapy administered as a single infusion, in the treatment of patients with relapsed and/or refractory multiple myeloma.
-
New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrated Deeper and Sustained Undetectable Minimal Residual Disease Outcomes in First-Line Chronic Lymphocytic Leukemia
12/11/2021
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data from two studies evaluating the efficacy and safety of IMBRUVICA® plus venetoclax as a potential fixed-duration treatment in adult patients with previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
-
New Clinical and Real-World Data Support Use of DARZALEX® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma
12/11/2021
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new analyses illustrating responses that first-line treatment with DARZALEX® -based regimens may be able to achieve, including a potential survival benefit for DARZALEX® in combination with lenalidomide and dexamethasone.
-
Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma
12/11/2021
The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of talquetamab.
-
A TikTok video went “viral” in November, claiming that vaccine regretters should take complex “detox” baths featuring ingredients such as borax.
-
Janssen Announces Respiratory Syncytial Virus (RSV) Adult Vaccine Candidate Maintains High Efficacy Regardless of Lower Respiratory Tract Disease Severity
12/7/2021
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced additional vaccine efficacy and safety data from its Phase 2b CYPRESS study of its respiratory syncytial virus (RSV) adult vaccine candidate.
-
Janssen to Showcase Progress on Respiratory Syncytial Virus (RSV) Vaccine Candidate at ESWI 2021
12/4/2021
The Janssen Pharmaceutical Companies of Johnson & Johnson announced it will present data from six company-sponsored studies in support of their respiratory syncytial virus adult vaccine candidate at the Eighth European Scientific Working Group on Influenza meeting.
-
Latest Phase 3 Data for First-in-Class TREMFYA® (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis
12/3/2021
The COSMOS study met its primary endpoint, with a significantly higher proportion of TREMFYA-treated patients (44.4 percent) versus placebo-treated patients (19.8 percent) achieving ACR20 response at week 24.
-
U.S. FDA Approves DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
12/1/2021
Approval marks the ninth indication for DARZALEX FASPRO®, the only subcutaneous anti-CD38 monoclonal antibody approved across a range of standard treatment regimens.
-
The approval was based on Phase II data from the PLEIADES study that showed patients treated with the combination therapy generated an overall response rate of 84.8%.